DCGI Orders Withdrawal of AstraZeneca's Cancer Drug Olaparib for Some Treatments
Moneylife Digital Team 23 May 2024
The Drug Controller General of India (DCGI) has asked drug regulators in all states and Union Territories to withdraw AstraZeneca's anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy.
In the order last week, DCGI has asked state regulators to direct manufacturers of the drug to discontinue marketing of Olaparib tablets 100mg and 150mg for the treatment of patients with germline breast cancer gene (gBRCA) mutation and advanced ovarian cancer and breast cancer due to potential adverse effects and submit the revised package insert.
On 13 August 2018, the Central Drugs Standard Control Organisation (CDSCO) approved Olaparib tablets 100mg and 150mg for the treatment of patients with gBRCA mutation and advanced ovarian cancer. 
AstraZeneca Pharma India Ltd submitted an application to withdraw the drug. The company also presented clinical evidence for withdrawing Olaparib tablets 100mg and 150mg.
After reviewing the application and clinical evidence, DCGI directed AstraZeneca to withdraw Olaparib tablets 100mg and 150mg and revise the package inserts. 
However, the drug may continue to be marketed for other approved indications, the apex drug regulator says.
15 Years after Launch, ASHAs’ Struggle with Healthcare Gaps
Nushaiba Iqbal (IndiaSpend) 20 May 2024
Suvarna Kamble (45), an accredited social health activist (ASHA) from Palghar, remembers a time when she brought a woman from Dhansar, a village in Palghar block of Palghar district, to a family planning clinic in Virar for a...
Covaxin: Nearly One-third Participants Reported Adverse Events, Says New Study
Moneylife Digital Team 17 May 2024
Nearly a third of participants who took Covaxin, the COVID-19 vaccine made by Bharat Biotech Ltd, reported adverse events of special interest (AESI), with women and those with allergies at higher risk, says a new study published on...
AstraZeneca Withdraws COVID-19 Vaccine Globally Citing Surplus of Newer Vaccines
Moneylife Digital Team 08 May 2024
Soon after the European Medicines Agency issued a notice that AstraZeneca's COVID-19 vaccine (now known as Vaxzevria) is no longer authorised for use, the pharmaceuticals company, citing a surplus of available updated vaccines that...
Why Did Centre Tell States Not To Act on Misleading AYUSH Ads, Asks SC, Orders Patanjali to Takedown Online Ads
Meera Emmanuel (Bar  and  Bench) 07 May 2024
The Supreme Court on Tuesday grilled the Central government on why it asked AYUSH authorities in states and union territories not to take any action against misleading advertisements under Rule 170 of the Drugs and Cosmetics Rules,...
Free Helpline
Legal Credit